Background: The impact of myocardial viral persistence on the clinical outcome of patients with dilated cardiomyopathy (DCM) is still open to question. Methods: Fifty-two patients with DCM were enrolled and followed for a median of 3.8 years with respect to death or heart transplantation. Studied patients were clinically stable for at least 6 months before hospitalization. They underwent coronary angiography and endomyocardial biopsy. Specimens were examined by histo- and immunohistochemistry, and the viral genomes of parvovirus B19, cytomegalovirus (CMV), Coxsackie B virus (CVB), and hepatitis B and C viruses were studied by real-time polymerase chain reaction. Results: Forty-two out of 52 patients were available for clinical follow-up. The viral genome was detected in the myocardium of 32 out of 42 patients. Among the viruses studied, CMV and CVB were the most frequently found. Nine out of 42 patients achieved the predefined study end point. No statistically significant correlation was found between the presence of a persistent viral genome and study end point. No statistically significant relationship between viral genomes studied and immunohistology results was detected. Conclusions: High prevalence of a viral genome in the myocardium of patients with DCM did not have an influence on their long-term clinical outcome.

Keywords:
Viral genome, Endomyocardial biopsy, Dilated cardiomyopathy, Heart failure
1.
Elliott P, Andersson B, Arbustini E, et al: Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270-276.
2.
McMurray J, Adamopoulos S, Anker S, et al: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012;1093:1-61.
3.
Dec GW Jr, Palacios IF, Fallon JT, et al: Active myocarditis in the spectrum of acute dilated cardiomyopathies - clinical features, histologic correlates, and clinical outcome. N Engl J Med 1985;312:885-890.
4.
Jin O, Sole MJ, Butany JW, et al: Detection of enterovirus RNA in myocardial biopsies from patients with myocarditis and cardiomyopathy using gene amplification by polymerase chain reaction. Circulation 1990;82:8-16.
5.
Caforio AL, Pankuweit S, Arbustini E, et al: Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2636-2648.
6.
Marholdt H, Wagner A, Deluigi CC, et al: Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006;114:1581-1590.
7.
Schulz JC, Hilliard A, Cooper L Jr, Rihal CS: Diagnosis and treatment of viral myocarditis. Mayo Clin Proc 2009;84:1001-1009.
8.
Andréoletti L, Lévêque N, Boulagnon C, Brasselet C, Fornes P: Viral causes of human myocarditis. Arch Cardiovasc Dis 2009;102:559-568.
9.
Schonian U, Crombach M, Maser S, Maisch B: Cytomegalovirus-associated heart muscle disease. Eur Heart J 1995;16:46-49.
10.
Kindermann I, Barth C, Mahfoud F, et al: Update on myocarditis. J Am Coll Cardiol 2012;59:779-792.
11.
Aretz HT: Myocarditis: the Dallas criteria. Hum Pathol 1987;18:619-624.
12.
Giacca M, Severini GM, Mestroni L, et al: Low frequency of detection by nested polymerase chain reaction of enterovirus ribonucleic acid in endomyocardial tissue of patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1033-1040.
13.
Pauschinger M, Bowles NE, Fuentes-Garcia FJ, et al: Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation 1999;99:1348-1354.
14.
Archard LC, Khan MA, Soteriou BA, et al: Characterization of Coxsackie B virus RNA in myocardium from patients with dilated cardiomyopathy by nucleotide sequencing of reverse transcription-nested polymerase chain reaction products. Hum Pathol 1998;29:578-584.
15.
Pankuweit S, Ruppert V, Eckhardt H, Strache D, Maisch B: Pathophysiology and aetiological diagnosis of inflammatory myocardial diseases with a special focus on parvovirus B19. J Vet Med B Infect Dis Vet Public Health 2005;52:344-347.
16.
Why HJ, Meany BT, Richardson PJ, et al: Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 1994;89:2582-2589.
17.
Kindermann I, Kindermann M, Kandolf R, et al: Predictors of outcome in patients with suspected myocarditis. Circulation 2008;118:639-648.
18.
Caforio AL, Calabrese F, Angelini A, et al: A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aethiopathogentic features at diagnosis. Eur Heart J 2007;28:1326-1333.
19.
Bowles NE, Rose ML, Taylor P, et al: End-stage dilated cardiomyopathy. Persistence of enterovirus RNA in myocardium at cardiac transplantation and lack of immune response. Circulation 1989;80:1128-1136.
20.
Bock CT, Klingel K, Kandolf R: Human parvovirus B19-associated myocarditis. N Engl J Med 2010;362:1248-1249.
21.
Martin AB, Webber S, Fricker FJ, et al: Acute myocarditis: rapid diagnosis by PCR in children. Circulation 1994;90:330-339.
22.
Bowles NE, Ni J, Kearney DL, et al: Detection of viruses in myocardial tissues by polymerase chain reaction: evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003;42:466-472.
23.
Lang RM, Bierig M, Devereux RB, et al: Recommendations for chamber quantification. Eur J Echocardiography 2006;7:79-108.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.